OBJECTIVE: HIV-infected patients are at increased risk for cardiovascular disease, which may be mediated in part by inflammation. Surrogate marker studies suggest an increased prevalence of vascular abnormalities in HIV infection. We examined the association of all-cause mortality in HIV-infected patients with carotid artery intima-media thickness (cIMT) and high-sensitivity C-reactive protein (hsCRP). DESIGN AND METHODS: Baseline risk factors, cIMT and hsCRP were prospectively measured in 327 HIV-infected participants. Follow-up time with median of 3.1 years was calculated from baseline to death or censored dated 7/31/07. Cox Proportional Hazards models were used to study risk factors associated with mortality. RESULTS: Thirty-eight (11.6%) of participants have died since study enrollment. cIMT was significantly higher in those who died and decedents were significantly more likely to have cIMT above the 75th percentile. Those who died had higher hsCRP than those alive and more had hsCRP values above 3mg/L. CD4 count was lower and log(10) viral load was higher in decedents, but antiretroviral regimens were similar in both groups. cIMT and hsCRP levels were significantly associated with mortality (HR = 2.74, 95% CI 1.26-5.97, p = 0.01; HR = 2.38, 95% CI 1.15-4.9, p = 0.02). CONCLUSIONS: Our study demonstrated a strong association of carotid IMT and hsCRP with all-cause death in this HIV-infected population despite being similar with respect to exposure to antiretroviral medications. Together these surrogate markers may be indices of chronic inflammation and unfavorable outcomes in HIV-positive patients.
OBJECTIVE:HIV-infectedpatients are at increased risk for cardiovascular disease, which may be mediated in part by inflammation. Surrogate marker studies suggest an increased prevalence of vascular abnormalities in HIV infection. We examined the association of all-cause mortality in HIV-infectedpatients with carotid artery intima-media thickness (cIMT) and high-sensitivity C-reactive protein (hsCRP). DESIGN AND METHODS: Baseline risk factors, cIMT and hsCRP were prospectively measured in 327 HIV-infectedparticipants. Follow-up time with median of 3.1 years was calculated from baseline to death or censored dated 7/31/07. Cox Proportional Hazards models were used to study risk factors associated with mortality. RESULTS: Thirty-eight (11.6%) of participants have died since study enrollment. cIMT was significantly higher in those who died and decedents were significantly more likely to have cIMT above the 75th percentile. Those who died had higher hsCRP than those alive and more had hsCRP values above 3mg/L. CD4 count was lower and log(10) viral load was higher in decedents, but antiretroviral regimens were similar in both groups. cIMT and hsCRP levels were significantly associated with mortality (HR = 2.74, 95% CI 1.26-5.97, p = 0.01; HR = 2.38, 95% CI 1.15-4.9, p = 0.02). CONCLUSIONS: Our study demonstrated a strong association of carotid IMT and hsCRP with all-cause death in this HIV-infected population despite being similar with respect to exposure to antiretroviral medications. Together these surrogate markers may be indices of chronic inflammation and unfavorable outcomes in HIV-positivepatients.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: Joseph G Feldman; Philip Goldwasser; Susan Holman; Jack DeHovitz; Howard Minkoff Journal: J Acquir Immune Defic Syndr Date: 2003-02-01 Impact factor: 3.731
Authors: Jie J Cao; Chau Thach; Teri A Manolio; Bruce M Psaty; Lewis H Kuller; Paulo H M Chaves; Joseph F Polak; Kim Sutton-Tyrrell; David M Herrington; Thomas R Price; Mary Cushman Journal: Circulation Date: 2003-06-23 Impact factor: 29.690
Authors: Priscilla Y Hsue; Joan C Lo; Arlana Franklin; Ann F Bolger; Jeffrey N Martin; Steven G Deeks; David D Waters Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Khaled Z Abd-Elmoniem; Aylin B Unsal; Sarah Eshera; Jatin R Matta; Nancy Muldoon; Dorothea McAreavey; Julia B Purdy; Rohan Hazra; Colleen Hadigan; Ahmed M Gharib Journal: Clin Infect Dis Date: 2014-08-25 Impact factor: 9.079
Authors: Alexandra Mangili; Raabia Ahmad; Robert L Wolfert; Jeffrey Kuvin; Joseph F Polak; Richard H Karas; Christine A Wanke Journal: Clin Infect Dis Date: 2013-12-11 Impact factor: 9.079
Authors: Martin Krsak; David M Kent; Norma Terrin; Christina Holcroft; Sally C Skinner; Christine Wanke Journal: AIDS Patient Care STDS Date: 2015-04-09 Impact factor: 5.078
Authors: Tatjana Rundek; Susan H Blanton; Susanne Bartels; Chuanhui Dong; Ami Raval; Ryan T Demmer; Digna Cabral; Mitchell S V Elkind; Ralph L Sacco; Moise Desvarieux Journal: Stroke Date: 2013-05-23 Impact factor: 7.914